Depression最新文献

{"title":"Reproductive and critical transitions in the lifespan of women patients with focus on menopause","authors":"Malkah T. Notman M.D.","doi":"10.1002/depr.3050030115","DOIUrl":"10.1002/depr.3050030115","url":null,"abstract":"","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 1-2","pages":"99-106"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030115","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82800478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Responsivity of allergic depressed subjects to antidepressant medication: A preliminary study","authors":"Barbara L. Kennedy M.D., Ph.D.,&nbsp;Richard L. Morris M.A.,&nbsp;John J. Schwab M.D.","doi":"10.1002/depr.3050030605","DOIUrl":"10.1002/depr.3050030605","url":null,"abstract":"<p>The prevalence of allergies in 52 patients with major depression was higher than that reported in the general population. After 8 weeks of treatment with either one of two serotonin reuptake inhibitors (SSRIs) or the heterocyclic antidepressant that we used in the clinical trials, the non-allergic depressed had a significantly greater response than the partial response of the allergic depressed as measured by decreases in HAM-D scores from baseline to the end of 8 weeks. Also, all of the non-allergic depressed responded to antidepressants whereas slightly fewer than one-half of the allergic depressed did so. Moreover, after the 8 weeks there were no differences between the HAM-D scores of the allergic depressed receiving active medication and those receiving placebos whereas the HAM-D scores of the non-allergic were significantly lower than those of the placebo group. Although the results are only preliminary observations, they have clinical implications. There is a need for investigators conducting clinical drug trials and for practitioners to obtain information about each depressed patient's allergy status. The discussion focuses on possible methodologic and other explanations for the lower responsivity of the depressed allergic than the non-allergic to antidepressants and also on the need for additional studies to determine whether the results can be replicated. Depression 3:286–289 (1995/1996). © 1996 WIey-Liss, Inc.</p>","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 6","pages":"286-289"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030605","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82953002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgments","authors":"Charles B. Nemeroff M.D., Ph.D","doi":"10.1002/depr.3050030610","DOIUrl":"https://doi.org/10.1002/depr.3050030610","url":null,"abstract":"","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 6","pages":"316"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030610","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138078552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alextthymia in male cannabis users: The role of comorbid depressive disorders","authors":"Gianfranco Spalletta M.D.,&nbsp;Alfonso Troisi M.D.,&nbsp;Augusto Pasini M.D.","doi":"10.1002/depr.3050030504","DOIUrl":"10.1002/depr.3050030504","url":null,"abstract":"<p>Whereas there is strong evidence for a high prevalence of alexithymia among patients with alcohol dependence and mixed substance abuse, no study has investigated the association between cannabis use and alexithymia. In this study, we assessed the prevalence of alexithymia, as measured by the 20-item revised Toronto Alexithymia Scale (TAS-20), in a group of newly abstinent cannabis abusers (N = 60) who abused cannabis exclusively. We found a large difference in the rate of alexithymia between cannabis abusers with and without comorbid DSM-III-R depressive disorders. Only 7% of nondepressed cannabis-abusing subjects were alexithymic. In contrast, 57% of cannabis abusers with comorbid major depression, dysthymia, or adjustment disorder with depressed mood were alexithymic. The prevalence rate of alexithymia among the cannabis abusers with comorbid depressive disorders was similar to that (50%) found in a control group of pure depressives, even though the TAS-20 F1 subscale discriminated between the two groups (depressed cannabis abusers had more difficulty identifying their feelings than pure depressives). These results suggest that a syndromal diagnosis of comorbid depression may be a major confounding variable in the assessment of alexithymia (as measured by the TAS total score) among subjects with cannabis abuse and dependence. Depression 3:246–249 (1995/1996). © 1996 Wiley-Liss, Inc.</p>","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 5","pages":"246-249"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030504","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79876218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sertraline in the treatment of women with postpartum major depression","authors":"Zachary N. Stowe M.D.,&nbsp;Jennifer Casarella,&nbsp;Jacque Landry,&nbsp;Charles B. Nemeroff M.D., Ph.D.","doi":"10.1002/depr.3050030109","DOIUrl":"10.1002/depr.3050030109","url":null,"abstract":"<p>No consensus has yet been reached as to whether or not postpartum depression (PPD) represents a distinct clinical entity. Despite the increasing evidence that gender differences may exist in antidepressant treatment response, there is an absence of studies in women with postpartum onset of major depression. The aim of this study was to assess the clinical efficacy of the selective serotonin reuptake inhibitor (SSRI), sertraline, in the treatment of women with a major depressive episode (MDE) that occurred within 6 months of childbirth using an 8 week, prospective, open-labelled design. Further, we sought to determine if the Edinburgh Postnatal Depression Scale (EPDS) was a useful instrument to monitor the clinical response to drug treatment. Twenty-six postpartum women who fulfilled DSM-IIIR criteria for major depressive episode, non-psychotic, with symptom onset within 6 months postpartum were enrolled in the study. Biweekly assessments included physician and self-rated depression measures. Twenty-one of the women (81%) completed the 8 week study; 20 women exhibited a salutary response as defined by &gt; 50% reduction from baseline in SIGH-D scores (mean reduction = 15.7 points). Fourteen women demonstrated complete symptom remission with recovery of function (SIGH-D &lt; 7, CGI = 1, GAP &gt; 80) upon completion of the 8 week study. Three women experienced significant side effects; these included gastrointestinal disturbance (n =1) and anorgasmia (n = 2). Our results indicate that: (1) sertraline is a highly efficacious and well-tolerated treatment for women with postpartum depression; (2) the EPDS is comparable to the BDI and SIGH-D for monitoring treatment response in women with postpartum onset MDE; (3) PPD (MDE onset within 4 weeks postpartum, as defined by DSM IV) required significantly less medication and tended to respond faster than MDE onset after 4 weeks postpartum; and (4) the rapid response rate underscores the need to conduct placebo-controlled studies in this population. Depression 3:49–55 (1995). © 1995 Wiley-Liss, Inc.</p>","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 1-2","pages":"49-55"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030109","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88012021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events in 583 valproate-treated patients","authors":"Joseph R. Calabrese M.D.,&nbsp;John W. Goethe M.D.,&nbsp;Allen Kayser M.D.,&nbsp;David B. Marcotte M.D.,&nbsp;John A. Monagin M.D.,&nbsp;Susan E. Kimmel M.D.,&nbsp;Andrew M. Brugger M.D.,&nbsp;David Morris Ph.D.,&nbsp;S. Hossein Fatemi M.D., Ph.D.","doi":"10.1002/depr.3050030506","DOIUrl":"10.1002/depr.3050030506","url":null,"abstract":"<p>Double-blind placebo-controlled studies indicate that valproate is an effective therapy for bipolar mania. The objective of this research was to evaluate the profile of adverse events associated with the medical management of bipolar disorder when valproate was administered with routine adjunctive psychotropic agents. A structured retrospective chart review for adverse events was done in 583 valproate-treated bipolar patients across five medical centers. Valproate was used for 3 months by 392 patients and &gt;1 year in 168. For 961 patient-years, 97% patients were treated concomitantly with other medications. Eighty-three percent of patients were comorbid, with clinically significant medical illnesses. The average total daily dose of valproate was approximately 1400 mg and serum level was 82 μg/ml. Consistent with prior reports in epilepsy, adverse events associated with valproate included (in order of decreasing prevalence) tremor, nausea, somnolence, hair changes/thinning, asthenia, diarrhea, weight gain, dizziness, abdominal pain/stomach cramping, benign thrombocytopenia, headaches, and vomiting. These data suggest that when valproate is openly administered with a wide array of other psychiatric medications over relatively long periods, as is frequently the case in routine clinical practice, the profile of valproate-related adverse events is similar to those already observed in the treatment of epilepsy. Depression 3:257–262 (1995/1996). © 1996 Wiley-Liss, Inc.</p>","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 5","pages":"257-262"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030506","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87274091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The American psychiatric press textbook of psychopharmacology. A. Schatzberg, C. Nemeroff (eds). American Psychiatric Press, Inc., Washington, DC, 1995. 896 pp","authors":"Joseph T. Coyk M.D.","doi":"10.1002/depr.3050030410","DOIUrl":"10.1002/depr.3050030410","url":null,"abstract":"","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 4","pages":"211-212"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030410","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86504211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menopause and mood","authors":"Suzanne Griffin M.D.","doi":"10.1002/depr.3050030110","DOIUrl":"10.1002/depr.3050030110","url":null,"abstract":"","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 1-2","pages":"56-59"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030110","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51503288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Placebo-controlled study of ABT-200 versus fluoxetine in the treatment of major depressive disorder","authors":"John J. Sramek Pharm.D.,&nbsp;Kenneth Kashkin M.D.,&nbsp;Olga Jasinsky,&nbsp;David Kardatzke Ph.D.,&nbsp;Sara Kennedy B.A.,&nbsp;Neal R. Cutler M.D.","doi":"10.1002/depr.3050030407","DOIUrl":"10.1002/depr.3050030407","url":null,"abstract":"<p>ABT-200 is a novel potential antidepressant which antagonizes both norepi-nephrine uptake and noradrenergic a₂ receptors. This single-site study conducted over 5 months compared the safely and efficacy of ABT-200 (titrated up to 280 mg/day) to a fixed dose offluoxetine (20 mg/day) and placebo in 216 patients meeting DSM-III-R criteria for major depressive disorder. Following a 1-week placebo lead-in phase, patients were randomized to receive ABT-200 (n = 72), fluoxetine (n = 72), or placebo (n = 72) for 9 weeks of double-blind treatment. At the end of the study there were no differences (P &gt; 0.05) in HAM-D total score changes from baseline between ABT-200-treated and placebo-treated patients, whose mean scores were reduced by 4.6 points (16.8%) and 6.4 points (23.3%), respectively. Patients on fluoxetine, however, showed statistically significant improvement over placebo on total HAM-D scores with a decrease of 8.6 points (30.5%,P &lt; 0.05). While there were no serious adverse events thought to be related to the study drug, 36.1% of ABT-200 patients discontinued the study due to adverse events, compared to only 5.6% of placebo patients and 4.2% offluoxetine patients. If ABT-200 produced the spectrum of biochemical effects in humans predicted from preclinical studies, our results suggest that these actions do not lead to antidepressant effects in general depressed outpatient populations. Depression 3:199–203 (1995). © 1995 Wiley-Liss, Inc.</p>","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 4","pages":"199-203"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030407","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84437671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depression as a brain disease","authors":"Lewis L. Judd M.D.","doi":"10.1002/depr.3050030304","DOIUrl":"10.1002/depr.3050030304","url":null,"abstract":"","PeriodicalId":11179,"journal":{"name":"Depression","volume":"3 3","pages":"121-124"},"PeriodicalIF":0.0,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/depr.3050030304","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76345129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}